Pelthos Therapeutics (NYSEAMERICAN:PTHS) Announces Earnings Results

Pelthos Therapeutics (NYSEAMERICAN:PTHS) posted its quarterly earnings results on Thursday. The company reported ($6.62) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $15.60 million for the quarter.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• ZELSUVMI revenue and prescriptions grew strongly: Q2 net product revenue rose 45% sequentially to $15.4 million, while prescribed units increased 48% to 11,925. The company reported more than 25,000 patients prescribed and over 8,000 unique HCP prescribers since launch.
• Market access and commercial execution continue to support demand. Commercial insurance coverage reached 59% and Medicaid coverage 100%, while the 67-territory sales force, PBM contracting, and a recent expert-consensus publication are expected to aid further adoption.
• Pelthos reiterated plans to launch the complementary products XEPI in the first quarter of 2027 and XEGLYZE in the third quarter of 2027. Management expects to leverage its existing sales infrastructure, limiting incremental commercial overhead.
• The company restated its first-quarter 2026 financial statements because of an error in fair-value accounting for related-party convertible debt. Management said the adjustment does not affect cash, revenue, operating expenses, operating loss, or cash flows, but the restatement adds financial-reporting risk.
• Pelthos remains loss-making and faces near-term cost pressure: Q2 net loss was $23.4 million, cash was $24.2 million, and an out-of-specification API issue caused a $0.9 million inventory write-off. Gross-to-net deductions are expected to rise from 29.6% toward the low-to-mid-30% range, or potentially higher if another payer contract is added.

Pelthos Therapeutics Price Performance

Shares of Pelthos Therapeutics stock traded up $0.60 during mid-day trading on Thursday, reaching $29.51. 33,322 shares of the stock traded hands, compared to its average volume of 27,838. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41. The business has a 50-day moving average of $27.39 and a 200 day moving average of $25.09. The stock has a market capitalization of $102.69 million, a PE ratio of -1.43 and a beta of 3.10. Pelthos Therapeutics has a fifty-two week low of $18.19 and a fifty-two week high of $37.50.

Analysts Set New Price Targets

Separately, Oppenheimer upped their price objective on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Insiders Place Their Bets

In other Pelthos Therapeutics news, Director Todd C. Davis bought 35,948 shares of the stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $27.82 per share, with a total value of $1,000,073.36. Following the purchase, the director directly owned 75,834 shares in the company, valued at $2,109,701.88. This trade represents a 90.13% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 1,638 shares of company stock valued at $43,107. Company insiders own 12.70% of the company’s stock.

Institutional Trading of Pelthos Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Ikarian Capital LLC increased its holdings in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after purchasing an additional 193,307 shares during the last quarter. Boothbay Fund Management LLC raised its holdings in shares of Pelthos Therapeutics by 279.8% during the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the period. J. Goldman & Co LP purchased a new stake in shares of Pelthos Therapeutics in the 4th quarter valued at approximately $2,418,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Pelthos Therapeutics during the 4th quarter worth approximately $1,085,000. Finally, Diadema Partners LP raised its position in Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after purchasing an additional 14,502 shares during the period. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).